查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070477

口服蛋白質及胜肽市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測

Oral Proteins and Peptides Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

口服蛋白質及胜肽市場規模、佔有率、成長及產業展望（2025-2034年）

2025年全球口服蛋白質及胜肽市場規模為33.6億美元，預計將從2026年的39.7億美元成長至2034年的91.7億美元，預測期內年複合成長率（CAGR）為11.03%。北美地區在2025年佔據市場主導地位，市場佔有率高達71.72%，主要得益於口服胜肽療法的積極商業化、先進的醫療基礎設施以及創新生技藥品的高滲透率。

口服蛋白質和胜肽類藥物代表了藥物遞送領域的一項重大進步，使得基於蛋白質和胜肽類的療法能夠透過片劑和膠囊而非注射劑給藥。這些治療方法提高了患者的用藥便利性，增強了治療依從性，並支持對慢性疾病進行早期療育。這一市場的發展得益於口服Semaglutide的商業性成功、醫生對口服肽類療法接受度的提高、對口服藥物遞送技術投資的增加，以及口服胰島素、口服甲狀旁腺激素類似物、GLP-2療法和減肥藥開發平臺的擴展。

市場規模及預測

  • 2025年市場規模：33.6億美元
  • 2026年市場規模：39.7億美元
  • 2034年市場規模：91.7億美元
  • 年複合成長率（2026-2034）：11.03%

預計在整個預測期內，糖尿病、肥胖症、內分泌失調和代謝性疾病的日益普遍將持續產生對口服胜肽療法的需求。

主要市場趨勢

人們越來越傾向於非侵入性治療方法

影響市場的最重要趨勢之一是人們越來越傾向於選擇非侵入性治療方法。便利性的提高、對注射焦慮的減少以及更高的遵守用藥性，使得患者越來越傾向於口服藥物而非注射療法。

口服GLP-1療法的核准顯示口服生物製劑具有巨大的商業性潛力。2025年12月，Novo Nordisk的Wegovy錠劑獲得FDA批准，進一步鞏固了人們對口服胜肽類體重管理療法的信心。

市場促進因素

慢性病盛行率增加

慢性疾病負擔的日益加重持續推動口服蛋白質和胜肽製劑的需求。由於第2型糖尿病、肥胖症、骨質疏鬆症和內分泌疾病等疾病需要長期治療，口服療法對患者和醫療保健提供者都極具吸引力。

根據世界衛生組織的資料，2022年全球約有16%的成年人患有肥胖症。患者數量的增加為口服胜肽療法提供了巨大的機會，因為口服胜肽療法的療效與注射療法相當。

口服GLP-1療法的廣泛應用

口服Semaglutide製劑取得商業性成功後，製藥公司正大力投資研發下一代口服生物製藥。隨著醫師信心增強和患者接受度提高，全球市場擴張速度加快。

市場限制因素

高昂的開發成本

由於製劑複雜、吸收增強技術、大規模臨床試驗以及特殊的生產需求，口服胜肽療法的研發成本仍然很高。這些因素增加了研發風險，並對中小型生物技術公司構成了障礙。

生物利用度低帶來的挑戰

由於蛋白質和胜肽類物質在消化道內容易被分解，因此很難被全身吸收。確保其生物有效性仍然是生產商面臨的最大科學挑戰之一。

市場機會

口服藥物傳遞技術的進步

吸收促進劑、保護性包衣和片劑遞送平台方面的創新開闢新的成長機會。這些技術使得更多生物製藥製劑能夠以口服製劑的形式開發，拓展其應用範圍，使其不再局限於糖尿病，也能用於治療骨質疏鬆症、肥胖症和內分泌疾病等。

2026年 3月，Entera Bio 提交了其口服骨質疏鬆症治療藥物 EB613 的簡化 III 期試驗方案，顯示其口服胜肽遞送技術日益成熟。

區域分析

北美洲

北美仍然是最大的區域市場，到2025年達到 24.1億美元。健全的保險償付制度、早期產品商業化以及口服 GLP-1 療法的快速普及，都支撐著該地區的市場主導地位。

預計到2026年，美國市場規模將達到約 26.2億美元，約佔全球整體銷售額的66%。

歐洲

受口服Semaglutide療法日益普及和相關保險償付政策的推動，歐洲市場預計將以 15.66%的年複合成長率成長。

亞太地區

預計到2026年，亞太地區的糖尿病市場規模將達到 4.6億美元，這主要得益於糖尿病患者數量龐大、醫療保健服務可及性提高以及對創新代謝療法的需求不斷成長。

拉丁美洲、中東和非洲

由於人們意識的提高、醫療保健基礎設施的擴大以及糖尿病和肥胖症的盛行率上升，預計這些地區將經歷適度成長。

領先企業投資口服 GLP-1 療法、口服胰島素計畫、口服 PTH 類似物和先進的藥物輸送技術，以鞏固其市場地位。

近期產業趨勢

  • 2025年 9月：EnteraBio 公佈了其口服 GLP-2 片劑的良好藥物動力學資料。
  • 2025年 6月：Protagonist Therapeutics 將 PN-477 指定為治療肥胖症的候選口服胜肽。
  • 2025年 2月：Rani Therapeutics 公佈了使用 RaniPill 技術進行口服Semaglutide給藥的積極臨床前資料。
  • 2024年 11月：Protagonist 公司報告指出，其口服胜肽類候選藥物 icotrokinra 的III 期試驗取得了積極結果。
  • 2024年 6月：Lani Therapeutics 與 Progen 合作開發口服減肥藥RT-114。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 大型公司管道分析
  • 主要產業趨勢（合併、收購、合作等）
  • 新產品發布：依主要公司分類
  • 主要國家和地區的監管趨勢

第5章 2021-2034年全球口服蛋白質及胜肽市場分析、洞察與預測

  • 市場分析、洞察與預測：依藥物類別
    • GLP-1胜肽
    • 生長抑制素類似物
    • PTH 類似物
    • GLP-2胜肽
    • 其他
  • 市場分析、洞察與預測：依治療領域
    • 代謝性疾病
    • 內分泌疾病
    • 其他
  • 市場分析、洞察與預測：依年齡層
    • 兒童
    • 成人
  • 市場分析、洞察與預測：依製劑
    • 片劑
    • 其他
  • 市場分析、洞察與預測：依通路
    • 醫院藥房
    • 零售藥局和藥房
    • 專科藥房和其他
  • 分析、洞察與預測：依地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美口服蛋白質及胜肽市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲口服蛋白質及胜肽市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區口服蛋白質與胜肽市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲口服蛋白質及胜肽市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲口服蛋白質及胜肽市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Novo Nordisk
    • Chiesi Group
    • EnteraBio Ltd.
    • Oramed
    • Protagonist Therapeutics Inc.
    • Biocon
    • Rani Therapeutics
Product Code: FBI116018

Oral Proteins and Peptides Market Size, Share, Growth and Industry Outlook (2025-2034)

The global oral proteins and peptides market was valued at USD 3.36 billion in 2025 and is projected to grow from USD 3.97 billion in 2026 to USD 9.17 billion by 2034, registering a CAGR of 11.03% during the forecast period. North America dominated the market with a 71.72% share in 2025, supported by the strong commercialization of oral peptide therapies, advanced healthcare infrastructure, and high adoption of innovative biologics.

Oral proteins and peptides represent a major advancement in drug delivery, enabling protein- and peptide-based therapies to be administered through tablets or capsules rather than injections. These therapies improve patient convenience, increase treatment adherence, and support earlier intervention in chronic disease management. The market is being driven by the commercial success of oral semaglutide, increasing physician acceptance of oral peptide therapies, growing investments in oral drug delivery technologies, and expanding development pipelines for oral insulin, oral PTH analogs, GLP-2 therapies, and obesity treatments.

Market Size and Forecast

  • 2025 Market Size: USD 3.36 Billion
  • 2026 Market Size: USD 3.97 Billion
  • 2034 Market Size: USD 9.17 Billion
  • CAGR (2026-2034): 11.03%

The increasing prevalence of diabetes, obesity, endocrine disorders, and metabolic diseases is expected to create sustained demand for oral peptide therapeutics throughout the forecast period.

Key Market Trends

Rising Preference for Non-Invasive Therapies

One of the most significant trends shaping the market is the growing preference for non-invasive treatment options. Patients increasingly favor oral medications over injectable therapies due to greater convenience, reduced needle anxiety, and improved adherence.

The approval of oral GLP-1 therapies has demonstrated strong commercial potential for oral biologics. In December 2025, Novo Nordisk received FDA approval for the Wegovy pill, further strengthening confidence in oral peptide-based weight management therapies.

Market Drivers

Increasing Prevalence of Chronic Diseases

The growing burden of chronic diseases continues to drive demand for oral proteins and peptides. Conditions such as type 2 diabetes, obesity, osteoporosis, and endocrine disorders require long-term treatment, making oral therapies highly attractive for both patients and healthcare providers.

According to WHO data, approximately 16% of adults globally were living with obesity in 2022. The expanding patient population creates significant opportunities for oral peptide therapies that offer efficacy comparable to injectable alternatives.

Growing Adoption of Oral GLP-1 Therapies

Commercial success of oral semaglutide products has encouraged pharmaceutical companies to invest heavily in next-generation oral biologics. Increasing physician confidence and patient acceptance are accelerating market expansion worldwide.

Market Restraints

High Development Costs

Developing oral peptide therapies remains expensive due to formulation complexity, absorption enhancement technologies, extensive clinical studies, and specialized manufacturing requirements. These factors increase development risks and create barriers for smaller biotechnology companies.

Low Bioavailability Challenges

Proteins and peptides are vulnerable to degradation within the gastrointestinal tract, making systemic absorption difficult. Ensuring consistent bioavailability remains one of the biggest scientific challenges for manufacturers.

Market Opportunities

Advances in Oral Drug Delivery Technologies

Innovations in absorption enhancers, protective coatings, and tablet delivery platforms are opening new growth opportunities. These technologies are enabling more biologics to be developed as oral formulations, expanding applications beyond diabetes into osteoporosis, obesity, and endocrine disorders.

In March 2026, Entera Bio submitted a streamlined Phase III protocol for its oral osteoporosis therapy EB613, highlighting the growing maturity of oral peptide delivery technologies.

Segment Analysis

By Drug Class

The GLP-1 Peptides segment dominated the market in 2025 due to strong commercial adoption and growing use in diabetes and obesity management. Novo Nordisk reported USD 3.4 billion in Rybelsus sales during 2025, reinforcing the segment's leadership.

The PTH Analogs segment is projected to record the fastest growth during the forecast period owing to promising osteoporosis treatment pipelines.

By Therapeutic Area

The Metabolic Disorders segment held the largest market share in 2025, driven by rising diabetes and obesity prevalence and increasing use of oral semaglutide therapies.

By Age Group

The Adult segment dominated the market as currently approved oral peptide therapies primarily target adult patients suffering from chronic diseases requiring long-term treatment.

By Formulation

The Tablets segment accounted for the largest share in 2025 due to ease of administration, patient convenience, and widespread physician acceptance.

By Distribution Channel

Retail Pharmacies & Drug Stores led the market in 2025 and are expected to account for approximately 71.5% of market share in 2026, supported by broad product availability and repeat prescription demand.

Regional Analysis

North America

North America remained the largest regional market, valued at USD 2.41 billion in 2025. Strong reimbursement systems, early product commercialization, and rapid adoption of oral GLP-1 therapies support regional dominance.

The U.S. market is projected to reach approximately USD 2.62 billion in 2026, representing around 66% of global revenues.

Europe

Europe is expected to grow at a CAGR of 15.66%, driven by increasing adoption of oral semaglutide therapies and supportive reimbursement policies.

Asia Pacific

Asia Pacific is projected to reach USD 0.46 billion in 2026, supported by large diabetic populations, improving healthcare access, and growing demand for innovative metabolic therapies.

Latin America and Middle East & Africa

These regions are expected to witness gradual growth due to increasing awareness, expanding healthcare infrastructure, and rising prevalence of diabetes and obesity.

Competitive Landscape

The market remains highly concentrated, with major companies focusing on commercialization, strategic collaborations, and pipeline expansion.

Key Companies

  • Novo Nordisk (Denmark)
  • Chiesi Group (Italy)
  • EnteraBio Ltd. (Israel)
  • Oramed Pharmaceuticals (U.S.)
  • Protagonist Therapeutics Inc. (U.S.)
  • Biocon (India)
  • Rani Therapeutics (U.S.)

Leading players are investing in oral GLP-1 therapies, oral insulin programs, oral PTH analogs, and advanced drug delivery technologies to strengthen their market positions.

Recent Industry Developments

  • September 2025: EnteraBio reported positive pharmacokinetic data for its oral GLP-2 tablet.
  • June 2025: Protagonist Therapeutics nominated PN-477 as an obesity-focused oral peptide candidate.
  • February 2025: Rani Therapeutics announced positive preclinical oral semaglutide delivery data using RaniPill technology.
  • November 2024: Protagonist reported positive Phase III results for oral peptide candidate icotrokinra.
  • June 2024: Rani Therapeutics partnered with ProGen for development of RT-114 oral obesity treatment.

Conclusion

The oral proteins and peptides market is entering a transformative growth phase as pharmaceutical companies continue shifting biologic therapies from injectable formats to convenient oral formulations. Growing chronic disease prevalence, strong commercial performance of oral GLP-1 therapies, technological advancements in drug delivery, and expanding development pipelines are expected to drive market expansion from USD 3.36 billion in 2025 to USD 9.17 billion by 2034. While challenges related to bioavailability and development costs remain, continued innovation and regulatory support are expected to create substantial opportunities for manufacturers and investors over the coming years.

Segmentation By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Region

By Drug Class * GLP-1 Peptides

  • Somatostatin Analogs
  • PTH Analogs
  • GLP-2 Peptides
  • Others

By Therapeutic Area * Metabolic Disorders

  • Endocrine Disorders
  • Others

By Age Group * Pediatric

  • Adult

By Formulation * Tablets

  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies & Drug Stores
  • Specialty Pharmacies & Others

By Region * North America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Therapeutic Area, Age Group, Formulation, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. GLP-1 Peptides
    • 5.1.2. Somatostatin Analogs
    • 5.1.3. PTH Analogs
    • 5.1.4. GLP-2 Peptides
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 5.2.1. Metabolic Disorders
    • 5.2.2. Endocrine Disorders
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adult
  • 5.4. Market Analysis, Insights and Forecast - By Formulation
    • 5.4.1. Tablets
    • 5.4.2. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies & Drug Stores
    • 5.5.3. Specialty Pharmacies & Others
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. GLP-1 Peptides
    • 6.1.2. Somatostatin Analogs
    • 6.1.3. PTH Analogs
    • 6.1.4. GLP-2 Peptides
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 6.2.1. Metabolic Disorders
    • 6.2.2. Endocrine Disorders
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adult
  • 6.4. Market Analysis, Insights and Forecast - By Formulation
    • 6.4.1. Tablets
    • 6.4.2. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies & Drug Stores
    • 6.5.3. Specialty Pharmacies & Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. GLP-1 Peptides
    • 7.1.2. Somatostatin Analogs
    • 7.1.3. PTH Analogs
    • 7.1.4. GLP-2 Peptides
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 7.2.1. Metabolic Disorders
    • 7.2.2. Endocrine Disorders
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adult
  • 7.4. Market Analysis, Insights and Forecast - By Formulation
    • 7.4.1. Tablets
    • 7.4.2. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies & Drug Stores
    • 7.5.3. Specialty Pharmacies & Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. GLP-1 Peptides
    • 8.1.2. Somatostatin Analogs
    • 8.1.3. PTH Analogs
    • 8.1.4. GLP-2 Peptides
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 8.2.1. Metabolic Disorders
    • 8.2.2. Endocrine Disorders
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adult
  • 8.4. Market Analysis, Insights and Forecast - By Formulation
    • 8.4.1. Tablets
    • 8.4.2. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies & Drug Stores
    • 8.5.3. Specialty Pharmacies & Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. GLP-1 Peptides
    • 9.1.2. Somatostatin Analogs
    • 9.1.3. PTH Analogs
    • 9.1.4. GLP-2 Peptides
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 9.2.1. Metabolic Disorders
    • 9.2.2. Endocrine Disorders
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adult
  • 9.4. Market Analysis, Insights and Forecast - By Formulation
    • 9.4.1. Tablets
    • 9.4.2. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies & Drug Stores
    • 9.5.3. Specialty Pharmacies & Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Oral Proteins and Peptides Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. GLP-1 Peptides
    • 10.1.2. Somatostatin Analogs
    • 10.1.3. PTH Analogs
    • 10.1.4. GLP-2 Peptides
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Therapeutic Area
    • 10.2.1. Metabolic Disorders
    • 10.2.2. Endocrine Disorders
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adult
  • 10.4. Market Analysis, Insights and Forecast - By Formulation
    • 10.4.1. Tablets
    • 10.4.2. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies & Drug Stores
    • 10.5.3. Specialty Pharmacies & Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Novo Nordisk
    • 11.2.2. Chiesi Group
    • 11.2.3. EnteraBio Ltd.
    • 11.2.4. Oramed
    • 11.2.5. Protagonist Therapeutics Inc.
    • 11.2.6. Biocon
    • 11.2.7. Rani Therapeutics

List of Tables

  • Figure 1: Global Oral Proteins and Peptides Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 3: Global Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025 & 2034
  • Figure 4: Global Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025 & 2034
  • Figure 5: Global Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025 & 2034
  • Figure 6: Global Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 7: Global Oral Proteins and Peptides Market Value Share (%), By Region, 2025 & 2034
  • Figure 8: North America Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 9: North America Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
  • Figure 10: North America Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
  • Figure 11: North America Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
  • Figure 12: North America Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 13: North America Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
  • Figure 14: North America Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
  • Figure 15: North America Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
  • Figure 16: North America Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 17: North America Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
  • Figure 18: North America Oral Proteins and Peptides Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Oral Proteins and Peptides Market Value Share (%), by Country, 2025
  • Figure 20: Europe Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 21: Europe Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
  • Figure 22: Europe Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
  • Figure 23: Europe Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
  • Figure 24: Europe Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 25: Europe Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
  • Figure 26: Europe Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
  • Figure 27: Europe Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
  • Figure 28: Europe Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 29: Europe Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
  • Figure 30: Europe Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
  • Figure 34: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
  • Figure 35: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
  • Figure 36: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 37: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
  • Figure 38: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
  • Figure 39: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
  • Figure 40: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
  • Figure 42: Asia Pacific Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 45: Latin America Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
  • Figure 46: Latin America Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
  • Figure 47: Latin America Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
  • Figure 48: Latin America Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 49: Latin America Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
  • Figure 50: Latin America Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
  • Figure 51: Latin America Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
  • Figure 52: Latin America Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
  • Figure 54: Latin America Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Drug Class, 2025
  • Figure 58: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Therapeutic Area, 2025 & 2034
  • Figure 59: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Therapeutic Area, 2025
  • Figure 60: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 61: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Age Group, 2025
  • Figure 62: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Formulation, 2025 & 2034
  • Figure 63: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Formulation, 2025
  • Figure 64: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), By Distribution Channel, 2025
  • Figure 66: Middle East & Africa Oral Proteins and Peptides Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Oral Proteins and Peptides Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Oral Proteins and Peptides Market Share (%), by Company, 2025